Icariin improves osteoporosis, inhibits the expression of PPARγ, C/EBPα, FABP4 mRNA, N1ICD and jagged1 proteins, and increases Notch2 mRNA in ovariectomized rats

Liu, Hengrui; Xiong, Yingquan; Zhu, Xiaofeng; Gao, Han; Yin, Sujuan; Wang, Jiefang; Chen, Guangming; Wang, Chaopeng; Xiang, Lu; Wang, Panpan; Ji, Fang; Zhang, Ronghua; Yang, Li

doi:10.3892/etm.2017.4128

Cited by 68 publications

(53 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Treatment of 10 -6 M ICA significantly increased ALP activity by the third day of treatment, and ALP activity remained elevated on the seventh day of treatment. These findings correspond to those from a previous study, which showed that ICA stimulated osteogenic differentiation (20) and inhibited adipocyte differentiation of rBMSCs (21).…”

Section: Discussionsupporting

confidence: 92%

“…Our previous study has shown that ICA can improve osteoporosis via the Notch signaling pathway (21), as well as the MAPK signaling pathway has also been shown to be involved in ICA-mediated osteogenic differentiation (26). In the present study, we use ICI as an ER signaling pathway antagonist, to investigate the correlation between ICA and the ER signaling pathway.…”

Section: Discussionmentioning

confidence: 94%

See 1 more Smart Citation

Icariin stimulates osteogenic differentiation and suppresses adipogenic differentiation of rBMSCs via estrogen receptor signaling

Peng

Pan

et al. 2018

Mol Med Report

Self Cite

View full text Add to dashboard Cite

Icariin (ICA) is a major active ingredient in Herba epimedii, which is commonly used as a Chinese herbal medicine for the treatment of osteoporosis. Previous studies have revealed that ICA exerted a protective effect against bone loss and increased bone regeneration; however, the association between ICA and estrogen receptor (ER) signaling remains unclear. The aim of the present study was to determine the effect of ICA on rat bone marrow stromal cells (rBMSCs). Cell Counting Kit‑8 assays were conducted to measure proliferation, alkaline phosphatase (ALP) activity was evaluated to assess osteoblast differentiation, and reverse transcription‑quantitative polymerase chain reaction as well as western blotting were performed to detect the expression of cellular and molecular markers of osteogenic or adipogenic differentiation. The results demonstrated that treatment of rBMSCs with 10‑6 M ICA stimulated rBMSC proliferation and ALP activity. Furthermore, ICA treatment increased the expression of the osteogenic markers runt‑related transcription factor 2, collagen type 1 and bone morphogenetic Protein 2; however, it also decreased the expression of the adipogenic differentiation markers peroxisome proliferator‑activated receptor gamma and CCAAT/enhancer‑binding protein α. Treatment of rBMSCs with ICI182780, an ER antagonist, blocked the effects of ICA. Taken together, these findings indicated that ICA may stimulate osteoblast differentiation and inhibit adipogenic differentiation via the activation of the ER signaling pathway. Therefore, ICA has the potential to serve as a therapeutic alternative for the prevention and treatment of osteoporosis.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 94%

Icariin stimulates osteogenic differentiation and suppresses adipogenic differentiation of rBMSCs via estrogen receptor signaling

Peng

Pan

et al. 2018

Mol Med Report

Self Cite

View full text Add to dashboard Cite

show abstract

“…CCAAT/enhancer-binding protein-alpha (C/EBP-α) (Kaestner, Christy, & Lane, 1990;Liu et al, 2017) and peroxisome proliferator-activated receptor-γ (PPAR-γ) (Hu, Tontonoz, & Spiegelman, 1995;Kang et al, 2018;Mueller et al, 2002) are the main transcription factors that induce mesenchymal stem cells to differentiate into adipocytes.…”

Section: Discussionmentioning

confidence: 99%

Preventive effect of small‐leaved Kuding tea (Ligustrum robustum) on high‐diet‐induced obesity in C57BL/6J mice

Yang

Liu

et al. 2020

Food Science & Nutrition

View full text Add to dashboard Cite

Small‐leaved Kuding tea (SLKDT; Ligustrum robustum) is a traditional Chinese tea. We systematically investigated the effect of SLKDT extract on obesity. SLKDT‐controlled weight gain in mice fed a high‐fat diet. Tissue specimen results showed that the SLKDT extract alleviated liver damage and fat accumulation. Meanwhile, SLKDT extract improved dyslipidemia by decreasing total cholesterol, triglycerides, and low‐density lipoprotein cholesterol levels and increasing high‐density lipoprotein cholesterol levels. Furthermore, SLKDT extract reduced alanine aminotransferase, alkaline phosphatase, and aspartate transaminase levels in the serum and liver tissues; decreased inflammatory cytokines, including interleukin (IL)‐1β, tumor necrosis factor‐α, interferon‐γ, and IL‐6; and increased the anti‐inflammatory cytokines, IL‐4 and IL‐10. The quantitative PCR results showed that SLKDT extract upregulated the mRNA expressions of peroxisome proliferator‐activated receptor (PPAR)‐α, lipoprotein lipase, carnitine palmitoyltransferase 1, and cholesterol 7 alpha hydroxylase and downregulated PPAR‐γ and CCAAT/enhancer‐binding protein‐alpha mRNA expressions in the obese mouse livers to reduce adipocyte differentiation and fat accumulation, promote fat oxidation, and improve dyslipidemia, thereby inhibiting the immune response and alleviating liver injury. SLKDT shows a potential for preventing obesity and regulating obesity‐related syndrome, so it is possible to be further developed as a novel treatment for fighting obesity.

show abstract

“…In a mouse calvarial defect model, icariin was transplanted in calcium phosphate cement and resulted in enhanced bone and blood vessel formation [10]. Other in vivo studies have reported significant cartilage repair in mice bearing osteochondral defects, as well as bone formation and antiadipogenic behavior ameliorating osteoporotic status of ovariectomized mice [11,12].…”

Section: Accepted Manuscriptmentioning

confidence: 99%

Bioinspired bone therapies using naringin: applications and advances

Lavrador

Gaspar

Mano

2018

Drug Discovery Today

View full text Add to dashboard Cite

The use of natural compounds for treating chronic bone diseases holds remarkable potential. Among these therapeutics, naringin, a flavanone glycoside, represents one of the most promising candidates owing to its multifaceted effect on bone tissues. This review provides an up-to-date overview on naringin applications in the treatment of bone disorders, such as osteoporosis and osteoarthritis, and further highlights its potential for stem cell pro-osteogenic differentiation therapies. A critical perspective on naringin clinical translation is also provided. The topic is discussed in light of recently developed biomaterial-based approaches that potentiate its bioavailability and bioactivity. Overall, the reported pro-osteogenic, antiresorptive and antiadipogenic properties establish this flavanone as an exciting candidate for application in bone tissue engineering and regenerative medicine.

show abstract

Icariin improves osteoporosis, inhibits the expression of PPARγ, C/EBPα, FABP4 mRNA, N1ICD and jagged1 proteins, and increases Notch2 mRNA in ovariectomized rats

Cited by 68 publications

References 42 publications

Icariin stimulates osteogenic differentiation and suppresses adipogenic differentiation of rBMSCs via estrogen receptor signaling

Icariin stimulates osteogenic differentiation and suppresses adipogenic differentiation of rBMSCs via estrogen receptor signaling

Preventive effect of small‐leaved Kuding tea (Ligustrum robustum) on high‐diet‐induced obesity in C57BL/6J mice

Bioinspired bone therapies using naringin: applications and advances

Contact Info

Product

Resources

About